Provider review
Mochi Health review: pricing, pharmacy, and evidence status
Released: · Last reviewed: · By Dr. Parmis
Mochi Health offers GLP-1 medications through telehealth. Every price, credential and pharmacy claim below is labeled by evidence status and read date.
Mochi Health's lowest price on file is $109/month (12-month membership: medication from $60 plus $49 a month), read November 20, 2026 on its own page. It does not name a dispensing pharmacy. On November 20, 2026 it scored 72.7/100 on GLP Ranked's v4.1 rubric, #5 of 15.
Rank and score
Mochi Health scores 72.7 of 100, #5 of 15 scored programs (November 20, 2026). The table shows every sub-check, the points earned and why; the methodology explains each one.
| ID | Category | Sub-check | Points | Note |
|---|---|---|---|---|
| PT1 | Pricing transparency | Drug price printed on the program's own page, read in the November 20, 2026 re-read | 5 of 5 | |
| PT2 | Pricing transparency | Price includes medication and care, or every required fee is printed beside it (2 if the program's own figures disagree) | 5 of 5 | |
| PT3 | Pricing transparency | Price at every dose knowable: same price at every dose, or a full dose ladder | 0 of 5 | medication priced by dose; only the starting-dose price is printed |
| PT4 | Pricing transparency | Plan term and billing interval stated (2 if the program's own pages disagree) | 5 of 5 | |
| CO1 | Clinical oversight | Prescribing medical group named (9), network label (5), physician executive only (3), arrangement described (2) | 9 of 9 | |
| CO2 | Clinical oversight | Prescribers' licensure or certification stated | 3 of 3 | |
| CO3 | Clinical oversight | Clinical lead (medical director or chief medical officer) named with credential | 0 of 3 | |
| PH1 | Pharmacy transparency | Dispensing pharmacy named (10), class described but not named (4), described only (2); brand-only programs whose pages say prescriptions go to the pharmacy you choose (10) | 2 of 10 | 'licensed partner pharmacies', none named |
| PH2 | Pharmacy transparency | Pharmacy class (503A/503B) or licensure stated; brand-only programs that send prescriptions to your chosen pharmacy (5) | 5 of 5 | |
| SU1 | Support | Two or more contact channels published (4), one (2) | 4 of 4 | |
| SU2 | Support | How to cancel is stated | 3 of 3 | |
| SU3 | Support | Refund terms are stated (any stated condition under which money is refunded or credited) | 3 of 3 | |
| RD1 | Regulatory disclosure | Compounded products described as not FDA-approved; brand-only programs (5) | 5 of 5 | |
| RD2 | Regulatory disclosure | No open FDA warning letter in FDA's index (read November 20, 2026) | 5 of 5 | |
| AC1 | Accessibility | Where it operates stated clearly (4); vague or conflicting statements (2) | 4 of 4 | |
| AC2 | Accessibility | Payment beyond a card stated (HSA/FSA or pay-later) | 3 of 3 | |
| AC3 | Accessibility | Can start month to month without a multi-month commitment | 3 of 3 | |
| AN | Total annual cost | semaglutide, 12 months: $1,308 (12-month membership: 12 × ($49 + $60 starting dose)), a minimum at half weight; benchmark $1,140 | 8.7 of 20 | 20 × benchmark ÷ cost |
| Total | 72.7 of 100 | |||
Strengths and limitations
Drawn from the sub-checks above, as read November 20-21, 2026.
- Strength: Drug price printed on the program's own page, read in the November 20, 2026 re-read.
- Strength: Price includes medication and care, or every required fee is printed beside it.
- Strength: Plan term and billing interval stated.
- Strength: Prescribing medical group named.
- Limitation: Price at every dose knowable: same price at every dose, or a full dose ladder: 0 of 5 (medication priced by dose; only the starting-dose price is printed).
- Limitation: Clinical lead: 0 of 3.
- Limitation: Dispensing pharmacy named: 2 of 10 ('licensed partner pharmacies', none named).
- Limitation: total annual cost scores 8.7 of 20.
Pricing by plan
| Medication | Formulation | Plan | Price | Source | Evidence |
|---|---|---|---|---|---|
| tirzepatide | compounded injectable | Month to month: medication from $90 at the starting dose, plus $79 monthly membership | $169/mo | provider page · read 2026-11-20 | Provider reported |
| tirzepatide | compounded injectable | 12-month membership: medication from $90 plus $49 a month | $139/mo | provider page · read 2026-11-20 | Provider reported |
| semaglutide | compounded injectable | Month to month: medication from $60 at the starting dose, plus $79 monthly membership | $139/mo | provider page · read 2026-11-20 | Provider reported |
| semaglutide | compounded injectable | 12-month membership: medication from $60 plus $49 a month | $109/mo | provider page · read 2026-11-20 | Provider reported |
"Provider reported" means the figure comes from the company's own site or intake flow and has not been independently corroborated by GLP Ranked.
Clinical model
Professional corporations: “Mochi provides practice management services to Mochi Medical, P.A., a Florida professional corporation, Mochi Medical CA, P.C., a California professional corporation, Mochi Medical KS, P.A., a Kansas professional corporation, and other affiliated medical servi…” (joinmochi.com, read 2026-11-10)
Prescribing entity named: Mochi Medical, P.A. (FL); Mochi Medical CA, P.C.; Mochi Medical NJ, P.C.; Mochi Medical KS, P.A..
Accreditation: we have not verified any accreditation or certification claim for Mochi Health against the issuing body. If a program cites one (for example LegitScript), check the issuer's public lookup before you rely on it.
Pharmacy & compliance
Pharmacy described but not named (read 2026-11-10) Pharmacy transparency is worth 15 of 100 points under our v4.1 rubric.
State availability
State-by-state availability is not independently verified.
Who this suits — and who it doesn't
Mochi Health may suit patients who want a standard-dose program and are comfortable proceeding without a named dispensing pharmacy disclosed up front.It is a weaker fit for patients who need written proof of pharmacy accreditation before paying; ask the company for it.
Terms to check before you pay: whether cancellation and refund terms were found on its pages is recorded in sub-checks SU2 and SU3 above (read November 21, 2026); published support response times: not published.
Sources
- FDA: Warning letters index (searched for this program) — Regulator database, captured 2026-11-20
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current October 1, 2026) — Regulator page, captured 2026-11-20
- FDA: Compounding: Inspections, Recalls, and other Actions (content current October 22, 2026) — Regulator list, captured 2026-11-21
Cite this page
GLP Ranked. "Mochi Health review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/mochi-health/
GLP Ranked. "Mochi Health review: pricing, pharmacy, and evidence status." https://glpranked.com/providers/mochi-health/